insulin sensitizer with negligible risk of hypoglycemia: A phase -I study. Int
J Diab and Metab. 2012,21(1):13-20
69. G
arber AJ , Abrahamson MJ , BarzilayJI, et al. AACE Comprehensive
Diabetes Management Algorithm 2013, Endocrine Practice. 2013;19:327-36.
70. M
arso SP, McGuire DK, Zinman B, et al.; DEVOTE Study Group. Efficacy
and safety of degludec versus glargine in type 2 diabetes. N Engl J Med .
2017;377:723-32
71. Yk
i-Jâ€™arvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and
hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine
100 U/ml in people with type 2 diabetes using basal insulin and oral
antihyperglycaemic drugs: the EDITION 2 randomize d 12- month trial
including 6-month extension. Diabetes Obes Metab. 2015;17:1142-9.
72. B
olli GB, Riddle MC, Bergenstal RM, et al.; EDITION 3 study investigators.